Limits...
Adenosine A(2A) Receptor and IL-10 in Peripheral Blood Mononuclear Cells of Patients with Mild Cognitive Impairment.

Arosio B, Mastronardi L, Gussago C, Nicolini P, Casè A, Ziglioli E, Bergamaschini L - Int J Alzheimers Dis (2011)

Bottom Line: Adenosine suppresses immune responses through the A(2A) receptor (A(2A)R).This study investigated the interleukin 10 (IL-10) genetic profile and the expression of A(2A)R in peripheral blood mononuclear cells (PBMCs) of patients with mild cognitive impairment (MCI), Alzheimer disease (AD), and age-matched controls to verify, if they may help distinguish different forms of cognitive decline.There was a significant linear increase in A(2A)R mRNA levels and A(2A)R density from mcd-MCI to a-MCI, with intermediate levels being found in AD.

View Article: PubMed Central - PubMed

Affiliation: Dipartimento di Medicina Interna, Università degli Studi di Milano & Unita di Geriatria, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Pace 9, 20122 Milano, Italy.

ABSTRACT
Adenosine suppresses immune responses through the A(2A) receptor (A(2A)R). This study investigated the interleukin 10 (IL-10) genetic profile and the expression of A(2A)R in peripheral blood mononuclear cells (PBMCs) of patients with mild cognitive impairment (MCI), Alzheimer disease (AD), and age-matched controls to verify, if they may help distinguish different forms of cognitive decline. We analyzed the IL-10 genotype and the expression of A(2A)R in 41 subjects with AD, 10 with amnestic MCI (a-MCI), 49 with multiple cognitive domain MCI (mcd-MCI), and 46 controls. There was a significant linear increase in A(2A)R mRNA levels and A(2A)R density from mcd-MCI to a-MCI, with intermediate levels being found in AD. The IL-10 AA genotype frequency was 67% in a-MCI, 46% in AD, 35% in mcd-MCI, and 20% in controls. These data suggest that the assessment of the IL-10 genotype and the expression of A(2A)R in PBMCs may be a valuable means of differentiating between a-MCI and mcd-MCI.

No MeSH data available.


Related in: MedlinePlus

A2AR mRNA levels (mean values ± standard error) in PBMCs from 41 AD, 10 a-MCI, 49 mcd-MCI, and 46 control (CT) subjects quantified by the 2-ΔΔCt method. Bonferroni post hoc: a-MCI versus controls and mcd-MCI patients (P < .05).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3101508&req=5

fig1: A2AR mRNA levels (mean values ± standard error) in PBMCs from 41 AD, 10 a-MCI, 49 mcd-MCI, and 46 control (CT) subjects quantified by the 2-ΔΔCt method. Bonferroni post hoc: a-MCI versus controls and mcd-MCI patients (P < .05).

Mentions: The qPCR analysis (Figure 1) revealed significantly higher (P < .05) A2AR mRNA levels in patients with a-MCI (3.77 ± 1.02) than in controls (2.12 ± 0.21) and in patients with mcd-MCI (1.42 ± 0.12). It is interesting to note that also A2AR density (Figures 2 and 3), expressed as A2AR/GAPDH ratio, was significantly higher in patients with a-MCI (0.71 ± 0.17) than in controls (0.62 ± 0.05) and in patients with mcd-MCI (0.43 ± 0.05). Both gene expression (2.50 ± 0.22) and density (0.50 ± 0.06) of the A2AR in PBMCs of AD patients were not significantly different from those of the controls (Figures 1 and 3). When the data were stratified according to the presence or absence of the ApoE ε4 allele, A2AR gene expression and receptor density were similar both in the ε4 carriers and noncarriers.


Adenosine A(2A) Receptor and IL-10 in Peripheral Blood Mononuclear Cells of Patients with Mild Cognitive Impairment.

Arosio B, Mastronardi L, Gussago C, Nicolini P, Casè A, Ziglioli E, Bergamaschini L - Int J Alzheimers Dis (2011)

A2AR mRNA levels (mean values ± standard error) in PBMCs from 41 AD, 10 a-MCI, 49 mcd-MCI, and 46 control (CT) subjects quantified by the 2-ΔΔCt method. Bonferroni post hoc: a-MCI versus controls and mcd-MCI patients (P < .05).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3101508&req=5

fig1: A2AR mRNA levels (mean values ± standard error) in PBMCs from 41 AD, 10 a-MCI, 49 mcd-MCI, and 46 control (CT) subjects quantified by the 2-ΔΔCt method. Bonferroni post hoc: a-MCI versus controls and mcd-MCI patients (P < .05).
Mentions: The qPCR analysis (Figure 1) revealed significantly higher (P < .05) A2AR mRNA levels in patients with a-MCI (3.77 ± 1.02) than in controls (2.12 ± 0.21) and in patients with mcd-MCI (1.42 ± 0.12). It is interesting to note that also A2AR density (Figures 2 and 3), expressed as A2AR/GAPDH ratio, was significantly higher in patients with a-MCI (0.71 ± 0.17) than in controls (0.62 ± 0.05) and in patients with mcd-MCI (0.43 ± 0.05). Both gene expression (2.50 ± 0.22) and density (0.50 ± 0.06) of the A2AR in PBMCs of AD patients were not significantly different from those of the controls (Figures 1 and 3). When the data were stratified according to the presence or absence of the ApoE ε4 allele, A2AR gene expression and receptor density were similar both in the ε4 carriers and noncarriers.

Bottom Line: Adenosine suppresses immune responses through the A(2A) receptor (A(2A)R).This study investigated the interleukin 10 (IL-10) genetic profile and the expression of A(2A)R in peripheral blood mononuclear cells (PBMCs) of patients with mild cognitive impairment (MCI), Alzheimer disease (AD), and age-matched controls to verify, if they may help distinguish different forms of cognitive decline.There was a significant linear increase in A(2A)R mRNA levels and A(2A)R density from mcd-MCI to a-MCI, with intermediate levels being found in AD.

View Article: PubMed Central - PubMed

Affiliation: Dipartimento di Medicina Interna, Università degli Studi di Milano & Unita di Geriatria, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Pace 9, 20122 Milano, Italy.

ABSTRACT
Adenosine suppresses immune responses through the A(2A) receptor (A(2A)R). This study investigated the interleukin 10 (IL-10) genetic profile and the expression of A(2A)R in peripheral blood mononuclear cells (PBMCs) of patients with mild cognitive impairment (MCI), Alzheimer disease (AD), and age-matched controls to verify, if they may help distinguish different forms of cognitive decline. We analyzed the IL-10 genotype and the expression of A(2A)R in 41 subjects with AD, 10 with amnestic MCI (a-MCI), 49 with multiple cognitive domain MCI (mcd-MCI), and 46 controls. There was a significant linear increase in A(2A)R mRNA levels and A(2A)R density from mcd-MCI to a-MCI, with intermediate levels being found in AD. The IL-10 AA genotype frequency was 67% in a-MCI, 46% in AD, 35% in mcd-MCI, and 20% in controls. These data suggest that the assessment of the IL-10 genotype and the expression of A(2A)R in PBMCs may be a valuable means of differentiating between a-MCI and mcd-MCI.

No MeSH data available.


Related in: MedlinePlus